570 related articles for article (PubMed ID: 26352219)
1. Challenges in the implementation of trastuzumab biosimilars: an expert panel's recommendations.
Pivot X; Aulagner G; Blay JY; Fumoleau P; Kaliski A; Sarkozy F; Limat S
Anticancer Drugs; 2015 Nov; 26(10):1009-16. PubMed ID: 26352219
[TBL] [Abstract][Full Text] [Related]
2. New frontiers in oncology: biosimilar monoclonal antibodies for the treatment of breast cancer.
Thill M
Expert Rev Anticancer Ther; 2015 Mar; 15(3):331-8. PubMed ID: 25539719
[TBL] [Abstract][Full Text] [Related]
3. ABP 980: promising trastuzumab biosimilar for HER2-positive breast cancer.
Paplomata E; Nahta R
Expert Opin Biol Ther; 2018 Mar; 18(3):335-341. PubMed ID: 29350568
[TBL] [Abstract][Full Text] [Related]
4. Recognizing and addressing challenges to the adoption of trastuzumab biosimilars and HER2-targeted therapies.
Whalen J
Am J Manag Care; 2020 Mar; 26(2 Suppl):S23-S31. PubMed ID: 32282172
[TBL] [Abstract][Full Text] [Related]
5. Evolving landscape of human epidermal growth factor receptor 2-positive breast cancer treatment and the future of biosimilars.
Jackisch C; Lammers P; Jacobs I
Breast; 2017 Apr; 32():199-216. PubMed ID: 28236776
[TBL] [Abstract][Full Text] [Related]
6. [Trastuzumab and its biosimilars].
Sarosiek T; Morawski P
Pol Merkur Lekarski; 2018 May; 44(263):253-257. PubMed ID: 29813044
[TBL] [Abstract][Full Text] [Related]
7. The evolution of biosimilars in oncology, with a focus on trastuzumab.
Nixon NA; Hannouf MB; Verma S
Curr Oncol; 2018 Jun; 25(Suppl 1):S171-S179. PubMed ID: 29910660
[TBL] [Abstract][Full Text] [Related]
8. Budget Impact Analysis of Biosimilar Trastuzumab for the Treatment of Breast Cancer in Croatia.
Cesarec A; Likić R
Appl Health Econ Health Policy; 2017 Apr; 15(2):277-286. PubMed ID: 27730538
[TBL] [Abstract][Full Text] [Related]
9. Integrating trastuzumab biosimilars and HER2-directed therapies into HER2-positive breast cancer management.
Cuellar S
Am J Manag Care; 2020 Mar; 26(2 Suppl):S32-S40. PubMed ID: 32282173
[TBL] [Abstract][Full Text] [Related]
10. Biosimilars lining up to compete with Herceptin--opportunity knocks.
Nelson KM; Gallagher PC
Expert Opin Ther Pat; 2014 Nov; 24(11):1149-53. PubMed ID: 25307085
[TBL] [Abstract][Full Text] [Related]
11. Current situation and challenges regarding biosimilars in Japan: an example of trastuzumab biosimilars for breast cancer.
Hara F; Tajima K; Tanabe K
Future Oncol; 2019 Apr; 15(12):1353-1361. PubMed ID: 30767568
[TBL] [Abstract][Full Text] [Related]
12. Trial Validates Biosimilar for Trastuzumab.
Cancer Discov; 2016 Jul; 6(7):686-7. PubMed ID: 27277256
[TBL] [Abstract][Full Text] [Related]
13. The Global Need for a Trastuzumab Biosimilar for Patients With HER2-Positive Breast Cancer.
Blackwell K; Gligorov J; Jacobs I; Twelves C
Clin Breast Cancer; 2018 Apr; 18(2):95-113. PubMed ID: 29525430
[TBL] [Abstract][Full Text] [Related]
14. Randomised clinical endpoint studies for trastuzumab biosimilars: a systematic review.
Coory M; Thornton K
Breast Cancer Res Treat; 2019 Jul; 176(1):17-25. PubMed ID: 30980209
[TBL] [Abstract][Full Text] [Related]
15. PF-05280014: A Trastuzumab Biosimilar.
Paik J
BioDrugs; 2018 Oct; 32(5):515-518. PubMed ID: 30280367
[TBL] [Abstract][Full Text] [Related]
16. The arrival of biosimilar monoclonal antibodies in oncology: clinical studies for trastuzumab biosimilars.
Barbier L; Declerck P; Simoens S; Neven P; Vulto AG; Huys I
Br J Cancer; 2019 Jul; 121(3):199-210. PubMed ID: 31257362
[TBL] [Abstract][Full Text] [Related]
17. Biosimilars for breast cancer.
Migliavacca Zucchetti B; Nicolò E; Curigliano G
Expert Opin Biol Ther; 2019 Oct; 19(10):1015-1021. PubMed ID: 31248290
[No Abstract] [Full Text] [Related]
18. [Biosimilars in oncology. Focus on SB3 studies.].
Del Re M; Del Mastro L
Recenti Prog Med; 2018 Nov; 109(11):531-539. PubMed ID: 30565572
[TBL] [Abstract][Full Text] [Related]
19. ABP 980: A Trastuzumab Biosimilar.
Dhillon S
BioDrugs; 2018 Oct; 32(5):511-514. PubMed ID: 30264234
[TBL] [Abstract][Full Text] [Related]
20. Biosimilar medicines used for cancer therapy in Europe: a review.
Santos SB; Sousa Lobo JM; Silva AC
Drug Discov Today; 2019 Jan; 24(1):293-299. PubMed ID: 30244082
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]